中国普通外科杂志 ›› 2011, Vol. 20 ›› Issue (2): 159-162.

• 基础研究 • 上一篇    下一篇

反应停对胆囊癌细胞影响的蛋白质组学研究

朱国民1|钟德玝2|李学明1|刘细平2   

  1. (1.南昌大学第一附属医院 普外一科|江西 南昌 330006; 2.中南大学湘雅二医院 普通外科|湖南 长沙 410011)
  • 收稿日期:2010-10-21 修回日期:2011-01-22 出版日期:2011-02-15 发布日期:2011-02-15
  • 通讯作者: 朱国民 E-mail:zgm1976@yahoo.com.cn
  • 作者简介:朱国民|南昌大学第一附属医院主治医师|主要从事普外科临床方面的研究。

Proteomics research of gallblader cancer cell line treatment with thalidomide

ZHU Guomin1, |ZHONG Dewu2, LI Xueming1, LIU Xiping2     

  1. (1.Department of General Surgery |the First Affiliated Hospital, Nanchang Univerity,Nanchang 330006,China|2.Department of General Surgery |the Second Xiangya Hospital, Central South University,Changsha 410011,China)
  • Received:2010-10-21 Revised:2011-01-22 Online:2011-02-15 Published:2011-02-15

摘要:

目的:筛选反应停作用于胆囊癌细胞后的相关差异蛋白,探讨反应停对胆囊癌细胞的作用机制。
方法:应用蛋白质组学技术分离出胆囊癌细胞的差异蛋白,细胞分为实验组和对照组,对两组差异蛋白进行分析和鉴定。
结果:共发现36个差异在2倍以上的蛋白点(P<0.05)。实验组中13个表达下调,23个上调。选择其中差异在3倍以上的10个蛋白质斑点作为差异表达的质谱分析,鉴定出7个蛋白质点。
结论:反应停对胆囊癌细胞有一定作用。通过差异蛋白质点进一步探索其对胆囊癌的作用点,可为研究反应停的抗胆囊癌的作用机制提供线索。

关键词: 胆囊肿瘤; 反应停; 蛋白质组学

Abstract:

Objective:To study the relevant differential expression proteins of GBC-SD cell line after treatment with thalidomide and the molecular mechanism.
Methods:Proteomic techniques and methods were used to separate the  differential expression proteins in GBC-SD cells after treated wiht that idomide (experiment group) and control group.
Results:The  differential expression proteins in experiment group and control group, whose spots variance was over 2-fold, were analysed  with PDQuest software,and found out 36 protein spots at difference level of expression(P<0.05), including 13 spots decreasing and 23 spots increasing  in experiment group. Then, 10 spots with more than 3-fold difference of  expression level were selected for anslysis, and 7 protein spots were identified.
Conclusions:Thalidomide has some effect on GBC-SD cells. Study on the function of differential protein can be as a basis for research on the mechanism of thalidomide treatment of gallbladder cancer.

Key words: Gallbladder Neoplasms, Thalidomide, Proteomics

中图分类号: 

  • R 735.8

[1]Rubegni P, Sbano P, De Aloe G,et al. Thalidomide in the treatment of Kaposi′s sarcoma[J]. Dermatology,2007,215(3):240-244.
[2]Ben M′barek L, Fardet L, Mebazaa A. A retrospective analysis of thalidomide therapy in non-HIV-related Kaposi′s sarcoma[J]. Dermatology, 2007,215(3):202-205.
[3]Radocha J, Maisnar V.  Low-dose thalidomide in refractory and relapsing multiple myeloma[J].  Vnitr Lek, 2007,53(2):129-134.
[4]Raina V, Sengar M, Shukla NK, et al. Complete response from thalidomide in angiosarcoma after treatment of breast cancer[J].J Clin Oncol, 2007,25(7):900-901.
[5]Efstathiou E, Troncoso P, Wen S,et al.  Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer[J].Clin Cancer Res,2007,13(4):1224-1231.
[6]Vaishampayan UN, Heilbrun LK, Shields AF,et al. Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma[J].Invest New Drugs,2007,25(1):69-75.
[7]张翠卿,唐东平,佐传田. MTT法在非小细胞肺癌优化治疗方案中的应用[J]. 现代肿瘤医学, 2007,15(11):1566-1568.
[8]Gómez-Roel X, Arrieta O, León-Rodríguez E. Prognostic  factors in gallbladder and biliary tract cancer[J]. Med Oncol,2007,24(1):77-83.
[9]Gorg A, Obermaier C, Boguth G, et al. The current state of two-dimensional electrophoresis with immobilized pH gradients[J]. Electrophoresis,  2000, 21(6): 1037-1053.
[10]Garrido C, Brunet M, Didelot C,et al.Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties[J]. Cell Cycle, 2006,5(22):2592-2601.
[11]Zoubeidi A, Zardan A, Wiedmann RM, et al.Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD[J].Cancer Res,2010,70(6):2307-2317.
[12]Rainey-Barger EK, Mkrtchian S, Tsai B.Dimerization of ERp29, a PDI-like protein, is essential for its diverse functions[J]. Mol Biol Cell, 2007,18(4):1253-1260.
[13]俞雅萍,晏春根. 糖尿病发病与内质网应激[J]. 中国临床康复, 2005,9(27):139-141.
[14]Dowling P, O′Driscoll L, O′Sullivan F,et al. Proteomic screening of glucose-responsive and glucose non-responsive MIN-6 beta cells reveals differential expression of proteins involved in protein folding, secretion and oxidative stress[J]. Proteomics, 2006,6(24):6578-6587.
[15]Feng Y, Mintian ZH, Xiwan M,et al. Protein profile of human hepatocarcinoma cell line SMMC-7721: Identification and functional analysis[J]. World J Gastroenterol, 2007,13(18):2608-2614.
[16]Raverdy S, Zhang Y, Foster J,et al.Molecular and biochemical characterization of nematode cofactor independent phosphoglycerate mutases[J]. Mol Biochem Parasitol, 2007,156(2):210-216.
[17]Mitra S, Cui J, Robbins PW, et al.A deeply divergent phosphoglucomutase (PGM) of Giardia lamblia has both PGM and phosphomannomutase activities[J].Glycobiology, 2010,20(10):1233-1240.
[18]Gulotta M, Qiu L, Desamero R, et al.Effects of cell volume regulating osmolytes on glycerol 3-phosphate binding to triosephosphate isomerase[J]. Biochemistry, 2007,46(35):10055-10062.
[19]Manco L, Ribeiro ML.Novel human pathological mutations. Gene symbol: TPI1. Disease: triosephosphate isomerase deficiency[J]. Hum Genet,2007,121(5):650-663.
[20]Glavas-Obrovac L, Suver M, Hikishima S,et al.Antiproliferative activity of purine nucleoside phosphorylase multisubstrate analogue inhibitors containing difluoromethylene phosphonic acid against leukaemia and lymphoma cells[J].Chem Biol Drug Des, 2010,75(4):392-399.
[21]Classen CF, Schulz AS, Sigl-Kraetzig M,et al. Successful HLA-identical bone marrow transplantation in a patient with PNP deficiency using busulfan and fludarabine for conditioning[J]. Bone Marrow Transplant, 2001,28(1):93-96.

[1] 赵新平1| 董山潮2. 内镜下塑管引流术在恶性梗阻性黄疸治疗中的临床观察[J]. 中国普通外科杂志, 2011, 20(8): 848-850.
[2] 华颂文| 杨竹林| 苗雄鹰. 胆总管腺癌PUMA和ABCG2的表达及其临床病理意义[J]. 中国普通外科杂志, 2011, 20(8): 818-822.
[3] 蔡云峰| 苏树英| 崔伟珍| 费凛| 李杰原. 可切除肝门部胆管癌术前胆道引流方式的选择[J]. 中国普通外科杂志, 2011, 20(8): 844-847.
[4] 顾劲扬|丁义涛. 恶性胆道肿瘤早期诊断技术与应用的研究进展[J]. 中国普通外科杂志, 2011, 20(8): 869-872.
[5] 刘俊1|李灼日2|毛先海1. Fascin在肝门胆管癌组织中的表达及临床意义[J]. 中国普通外科杂志, 2011, 20(6): 647-650.
[6] 喻智勇| 黄汉飞| 蔡强| 林杰. 以间歇性黄疸为主要临床表现的肝门部胆管癌1例[J]. 中国普通外科杂志, 2011, 20(3): 321-322.
[7] 尹强1|周海燕2. LY294002对胆管癌细胞凋亡的影响[J]. 中国普通外科杂志, 2011, 20(2): 129-132.
[8] 胡松1|蔡晓棠2|沈汉斌1|张少炎2|楼朝阳2. survivin shRNA表达质粒对GBC-SD细胞生长的抑制及对化疗敏感性的影响[J]. 中国普通外科杂志, 2011, 20(2): 154-158.
[9] 谭兴国|杨竹林|苗雄鹰. 胆囊良恶性病变组织中DNApkcs和Ku70的表达及其临床病理意义[J]. 中国普通外科杂志, 2011, 20(2): 163-168.
[10] 菅志远|沈先锋|周猛|周平|张敏|兰明银. 肝门部胆管癌患者的手术治疗[J]. 中国普通外科杂志, 2011, 20(2): 114-118.
[11] 徐方贵1|顾劲扬2|柏建岭3|仇毓东2. 恶性阻塞性黄疸术前胆道引流的有效性和安全性的荟萃分析[J]. 中国普通外科杂志, 2011, 20(2): 123-128.
[12] 刘薇|汤恢焕. 维拉帕米改善QBC939对顺铂耐药的实验研究[J]. 中国普通外科杂志, 2011, 20(2): 133-135.
[13] 郑建勇1| 李擒龙2| 董春燕3| 赵青川1| 杜建军1| 李纪鹏1| 晏伟2| 杨广顺4. Apr-1基因对胆管癌细胞QBC939细胞周期基因表达的影响[J]. 中国普通外科杂志, 2010, 19(9): 997-1000.
[14] 刘薇| 汤恢焕. 外源性IL-6对胆管癌细胞的抗凋亡作用及其对Bcl-2 mRNA的调控[J]. 中国普通外科杂志, 2010, 19(8): 871-874.
[15] 高明1| 项和平1| 耿小平1| 张长乐2. 肝门部胆管癌的诊断治疗[J]. 中国普通外科杂志, 2010, 19(8): 896-898.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 黄国民, 郑连文, 房学东, 刘林林. 胃癌穿孔的外科治疗[J]. 中国普通外科杂志, 2009, 18(10): 7 .
[2] 杨彬, 程石, 闫文貌, 宋茂民. NF-κB活化在氯化钆诱导ANP肺泡巨噬细胞凋亡中的作用[J]. 中国普通外科杂志, 2009, 18(9): 922 -925 .
[3] 廖霄斌, 赵晋明, 李介秋, 谢小丰. 腹腔镜肝包虫外囊剥离联合胆囊切除1例[J]. 中国普通外科杂志, 2009, 18(9): 931 .
[4] 卞育海, 曹晖, 郁丰荣, 陈治平, 吴志勇. 奥沙利铂联合5-FU术前动脉化疗对进展期胃癌的临床疗效[J]. 中国普通外科杂志, 2009, 18(9): 955 -959 .
[5] 钟颖, 孙强, 徐雅莉. 30年收治乳腺癌的发病趋势[J]. 中国普通外科杂志, 2009, 18(11): 1111 -1115 .
[6] 杨波, 孙冬林, 张丰, 陈学敏, 杨春. 改良胸前壁入路腔镜手术治疗甲状腺疾病:附66例报告[J]. 中国普通外科杂志, 2009, 18(11): 1142 -1145 .
[7] 王江涛, 王捷, 欧陕兴, 乔国庆, 唐咸国, 李小荣, 蔡俊杰. 乳腺癌裸鼠骨转移模型的建立及评估[J]. 中国普通外科杂志, 2009, 18(11): 1156 -1160 .
[8] 刘升平, 莫朝晖, 王国慧, 张大伟, 朱晒红. 腹腔镜下改良Roux-en-Y胃空肠转流术治疗2型糖尿病:附11例报告[J]. 中国普通外科杂志, 2009, 18(11): 1171 -1174 .
[9] 舒畅, 何昊, 姜晓华, 李全明, 黎明, 李鑫. 特殊类型腹主动脉瘤的诊疗体会[J]. 中国普通外科杂志, 2009, 18(12): 1233 -1237 .
[10] 王正林, 胡祥, 梁品. 趋化因子受体CXCR4在胃癌中的表达及其意义[J]. 中国普通外科杂志, 2009, 18(12): 1275 -1279 .